South Korea · Delayed Price · Currency is KRW L&C BIO Co.,LTD Statistics
Total Valuation
L&C BIO Co.,LTD has a market cap or net worth of KRW 1.59 trillion. The enterprise value is 1.65 trillion.
| Market Cap | 1.59T |
| Enterprise Value | 1.65T |
Important Dates
The last earnings date was Tuesday, March 24, 2026.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
L&C BIO Co.,LTD has 24.85 million shares outstanding. The number of shares has increased by 4.81% in one year.
| Current Share Class | 24.85M |
| Shares Outstanding | 24.85M |
| Shares Change (YoY) | +4.81% |
| Shares Change (QoQ) | +8.20% |
| Owned by Insiders (%) | 26.00% |
| Owned by Institutions (%) | 11.20% |
| Float | 17.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.58 |
| PB Ratio | 7.61 |
| P/TBV Ratio | 22.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 126.36 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 145.04, with an EV/FCF ratio of -509.48.
| EV / Earnings | -11.97 |
| EV / Sales | 19.34 |
| EV / EBITDA | 145.04 |
| EV / EBIT | n/a |
| EV / FCF | -509.48 |
Financial Position
The company has a current ratio of 0.59, with a Debt / Equity ratio of 0.44.
| Current Ratio | 0.59 |
| Quick Ratio | 0.26 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | 7.91 |
| Debt / FCF | -28.41 |
| Interest Coverage | 0.58 |
Financial Efficiency
Return on equity (ROE) is -55.36% and return on invested capital (ROIC) is 1.17%.
| Return on Equity (ROE) | -55.36% |
| Return on Assets (ROA) | 0.46% |
| Return on Invested Capital (ROIC) | 1.17% |
| Return on Capital Employed (ROCE) | 1.56% |
| Weighted Average Cost of Capital (WACC) | 12.64% |
| Revenue Per Employee | 606.22M |
| Profits Per Employee | -979.96M |
| Employee Count | 141 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.89 |
Taxes
| Income Tax | -21.68B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +265.88% in the last 52 weeks. The beta is 1.61, so L&C BIO Co.,LTD's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | +265.88% |
| 50-Day Moving Average | 81,916.00 |
| 200-Day Moving Average | 55,907.00 |
| Relative Strength Index (RSI) | 46.02 |
| Average Volume (20 Days) | 197,662 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&C BIO Co.,LTD had revenue of KRW 85.48 billion and -138.17 billion in losses. Loss per share was -5,819.37.
| Revenue | 85.48B |
| Gross Profit | 45.39B |
| Operating Income | 3.42B |
| Pretax Income | -160.03B |
| Net Income | -138.17B |
| EBITDA | 11.65B |
| EBIT | 3.42B |
| Loss Per Share | -5,819.37 |
Balance Sheet
The company has 36.82 billion in cash and 92.20 billion in debt, with a net cash position of -55.38 billion or -2,228.75 per share.
| Cash & Cash Equivalents | 36.82B |
| Total Debt | 92.20B |
| Net Cash | -55.38B |
| Net Cash Per Share | -2,228.75 |
| Equity (Book Value) | 208.53B |
| Book Value Per Share | 8,051.71 |
| Working Capital | -98.61B |
Cash Flow
In the last 12 months, operating cash flow was 12.56 billion and capital expenditures -15.81 billion, giving a free cash flow of -3.25 billion.
| Operating Cash Flow | 12.56B |
| Capital Expenditures | -15.81B |
| Depreciation & Amortization | 8.23B |
| Net Borrowing | 24.62B |
| Free Cash Flow | -3.25B |
| FCF Per Share | -130.61 |
Margins
Gross margin is 53.10%, with operating and profit margins of 4.00% and -161.65%.
| Gross Margin | 53.10% |
| Operating Margin | 4.00% |
| Pretax Margin | -187.23% |
| Profit Margin | -161.65% |
| EBITDA Margin | 13.63% |
| EBIT Margin | 4.00% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.08%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.08% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.81% |
| Shareholder Yield | -4.74% |
| Earnings Yield | -8.70% |
| FCF Yield | -0.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 12, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Oct 12, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
L&C BIO Co.,LTD has an Altman Z-Score of 2.35 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.35 |
| Piotroski F-Score | 5 |